Half-year report · HY
7745.TEDINET S100X328
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥30.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥67.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥30.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥3.2bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥9.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.8bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥69.3bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥69.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥66.7bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥25.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥26.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥44.2bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥42.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥38.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥13.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥62.25 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥235.63 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.38 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥62.19 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥235.41 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.32 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 63.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 99
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥13.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥13.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥799m |
| America Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.4bn |
| America Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.4bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥52m |
| America Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥1m |
| America Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| America Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4m |
| America Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥139m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥4.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.9bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.7bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥328m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥277m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.7bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥85m |
| Europe Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥285m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥285m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥14m |
| Europe Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥4.4bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥4.4bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Europe Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥24m |
| Japan Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥9.9bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥7.9bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥366m |
| Japan Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥8.1bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.1bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.5bn |
| Japan Semiconductor Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Japan Semiconductor Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Japan Semiconductor Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4m |
| Japan Semiconductor Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.6bn |
| Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥17.2bn |
| Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥13.5bn |
| Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.7bn |
| Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥679m |
| Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥21.6bn |
| Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥11.8bn |
| Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥9.8bn |
| Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.7bn |
| Semiconductor Related Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Semiconductor Related Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Semiconductor Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4m |
| Semiconductor Related Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥14.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥14.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.2bn |
| America Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| America Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥156m |
| America Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥65m |
| America Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| America Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| America Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥144m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.8bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥307m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.8bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥229m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥199m |
| Europe Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥346m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥346m |
| Europe Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Europe Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥0 |
| Europe Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Europe Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥221m |
| Japan Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥9.4bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥301m |
| Japan Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥8.7bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Japan Semiconductor Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| Japan Semiconductor Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| Japan Semiconductor Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥16.8bn |
| Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.3bn |
| Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥543m |
| Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥22.5bn |
| Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.7bn |
| Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥10.9bn |
| Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| Semiconductor Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| Semiconductor Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| Semiconductor Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 620
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 1674000 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.0604 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 1128000 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0407 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 804000 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0290 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 739000 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0267 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 676000 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0244 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 606000 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0219 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 531000 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0192 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 490000 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0177 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 397000 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0143 | |
| Number of shares held | InterimInstant | 11440000 | |
| Shareholding ratio | InterimInstant | 0.4126 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 120100 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 27655100 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 276551 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 70008 | |
| Number of shares issued shares voting rights | InterimInstant | 27845208 | |
| Number of voting rights issued shares voting rights | InterimInstant | 276551 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 120100 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 120100 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.0043 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 120100 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 120100 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.0043 | |
| Cash and deposits | Prior1YearInstant | 13346000000 | JPY |
| Cash and deposits | InterimInstant | 13819000000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 16567000000 | JPY |
| Notes and accounts receivable trade and contract assets | InterimInstant | 13467000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 9758000000 | JPY |
| Merchandise and finished goods | InterimInstant | 10963000000 | JPY |
| Work in process | Prior1YearInstant | 4373000000 | JPY |
| Work in process | InterimInstant | 5426000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 5872000000 | JPY |
| Raw materials and supplies | InterimInstant | 5763000000 | JPY |
| Other ca | Prior1YearInstant | 1829000000 | JPY |
| Other ca | InterimInstant | 1837000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |